A Study With Primatrix Dermal Repair Scaffold For The Treatment Of Diabetic Foot Ulcers

This study has suspended participant recruitment.
(Site selection)
Information provided by (Responsible Party):
TEI Biosciences Inc.
ClinicalTrials.gov Identifier:
First received: January 4, 2011
Last updated: May 11, 2015
Last verified: May 2015
The purpose of this study is to compare the clinical and economic effectiveness of PriMatrix and Standard of Care in the treatment of diabetic foot ulcers (DFUs) in subjects with controlled diabetes mellitus and without significantly compromised arterial circulation.

Condition Intervention
Foot Ulcer, Diabetic
Device: PriMatrix
Other: Standard of Care

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multi-Center, Prospective, Randomized Study With Primatrix Dermal Repair Scaffold For The Treatment Of Diabetic Foot Ulcers

Resource links provided by NLM:

Further study details as provided by TEI Biosciences Inc.:

Primary Outcome Measures:
  • Percent of study ulcers healed [ Time Frame: 12 weeks post-randomization ] [ Designated as safety issue: No ]
    Percent of study ulcers healed at week 12 post-randomization

Secondary Outcome Measures:
  • Cost of Treatment [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 30
Study Start Date: December 2010
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
PriMatrix applied to appropriately debrided wound bed and covered with a non-adherent dressing. Dressings applied to maintain moist wound therapy.
Device: PriMatrix
Following sharp debridement, application of PriMatrix dermal repair scaffold in conjunction with moist wound therapy
Active Comparator: Standard of Care
Non adherent dressing applied to appropriately debrided wound bed and moist wound therapy maintained.
Other: Standard of Care
Following sharp debridement, moist wound therapy

Detailed Description:
Subjects will be considered for screening upon meeting initial eligibility criteria. After a 2 week screening period, subject will be randomized and enrolled if additional criteria is met. In particular, if wound size has decreased by greater than 40%, subject will be considered a screen fail and randomization will not take place. If all criteria including wound size at Week 3 is met, subject will be randomized and enrolled. Subjects will return weekly for a maximum of 12 weeks, or whenever healing occurs and then once more for a confirmation of healing. Week 24 will consist of a phone call to the subject to complete QOL surveys.

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men or women ≥ 18 years of age and able to give their own consent
  • Type I or Type II diabetes with investigator-confirmed reasonable metabolic control
  • Study ulcer has a Wagner grade of 1 or 2
  • Study ulcer size of at least 1 cm2, but not exceeding 20 cm2 in area after debridement
  • A full thickness diabetic foot ulcer located on the foot or ankle
  • An ulcer which has been in existence for a minimum of 30 days, prior to the day of screening.

Exclusion Criteria:

  • Suspected or confirmed signs/symptoms of wound infection
  • Wounds with exposed bone or tendon
  • Hypersensitivity to bovine collagen
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01270633

United States, Georgia
Cumming, Georgia, United States, 30041
United States, Michigan
Covenant Medical Center
Saginaw, Michigan, United States, 48602
Puerto Rico
Professional Hospital
Guaynabo, Puerto Rico, 00717
Caribbean Clinical Trials
Hato Rey, Puerto Rico, 00918
Dr. Pila Metropolitan Hospital Wound Healing Center
Ponce, Puerto Rico, 00717
Doctors' Center Hospital of San Juan
San Juan, Puerto Rico, 00918
Wound and Ulcer Care Clinic of San Juan
San Juan, Puerto Rico, 00918
Wilma N. Vazquez Hospital
Vega Baja, Puerto Rico, 00694
Sponsors and Collaborators
TEI Biosciences Inc.
Study Chair: Yiannis Monovoukas, PhD TEI
  More Information

No publications provided

Responsible Party: TEI Biosciences Inc.
ClinicalTrials.gov Identifier: NCT01270633     History of Changes
Other Study ID Numbers: TEI-004
Study First Received: January 4, 2011
Last Updated: May 11, 2015
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Diabetic Foot
Foot Ulcer
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Angiopathies
Diabetic Neuropathies
Endocrine System Diseases
Foot Diseases
Leg Ulcer
Pathologic Processes
Skin Diseases
Skin Ulcer
Vascular Diseases

ClinicalTrials.gov processed this record on November 25, 2015